Overview

A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities

Status:
COMPLETED
Trial end date:
2024-08-13
Target enrollment:
Participant gender:
Summary
The main purpose of this study was to evaluate the safety and tolerability of RGT001-075 in healthy participants with obesity
Phase:
PHASE2
Details
Lead Sponsor:
Regor Pharmaceuticals Inc.